ADMA Biologics (NASDAQ: ADMA) proposes sale of option-exercise shares on 03/09/2026

Rhea-AI Filing Summary

ADMA Biologics submitted a Form 144 reporting proposed sales of Common Stock tied to option exercises, all dated 03/09/2026. The submission lists five exercise lots: 2,500, 1,250, 2,646, 1,525, and 2,175 shares, each described as "Stock Option Exercise" with the original grant dates shown.

Insights

Corporate Governance Analyst

Form 144 notifies proposed sales of option-derived common stock on 03/09/2026.

The filing lists five separate option-exercise lots by grant date and share counts, indicating planned dispositions through a brokeral arrangement. This is a routine disclosure that documents intent to sell restricted or control shares under Rule 144.

Cash-flow treatment and ultimate sale timing are not stated; subsequent filings or a broker report would show executed transactions if and when sales occur.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Fidelity Brokerage Services, LLC Attention: 10b5-1 Group 2 Contra Way T2L Merrimack NH 03054	10096	155377	238159176	03/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/09/2026	Stock Option Exercise - Options Granted February 14, 2017	Issuer			2500	03/09/2026	Cash
Common Stock	03/09/2026	Stock Option Exercise - Options Granted June 5, 2019	Issuer			1250	03/09/2026	Cash
Common Stock	03/09/2026	Stock Option Exercise - Options Granted August 19, 2020	Issuer			2646	03/09/2026	Cash
Common Stock	03/09/2026	Stock Option Exercise - Options Granted February 25, 2021	Issuer			1525	03/09/2026	Cash
Common Stock	03/09/2026	Stock Option Exercise - Options Granted July 19, 2021	Issuer			2175	03/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ADMA's Form 144 filing report?

It reports proposed sales of common stock tied to option exercises on 03/09/2026. The filing lists five exercise lots of 2,500; 1,250; 2,646; 1,525; and 2,175 shares, each described with its original option grant date.

Does the Form 144 mean the shares were sold for ADMA (ADMA)?

No. Form 144 notifies intent to sell under Rule 144; it does not confirm sale completion. Execution and proceeds are recorded only if and when transactions settle and appropriate broker reports are filed.

Who is handling the proposed sales in ADMA's filing?

The filing references Fidelity Brokerage Services, LLC and its 10b5-1 group as the broker/agent associated with the listed transactions dated 03/09/2026. The broker would report completed trades if executed.

Are the amounts in ADMA's Form 144 the total outstanding shares?

No. The listed numbers are share lots tied to specific option exercises only. They are not labeled as shares outstanding or as an aggregate company total in the filing excerpt provided.